Literature DB >> 17958690

Post-radiofrequency ablation syndrome after percutaneous radiofrequency of abdominal tumours: one centre experience and review of published works.

G Carrafiello1, D Laganà, A Ianniello, G Dionigi, R Novario, C Recaldini, M Mangini, S Cuffari, C Fugazzola.   

Abstract

The aim of this study was to evaluate prospectively post-radiofrequency ablation (RFA) syndrome and to determine its effect on the quality of life in the 15 days after percutaneous RFA treatment. We carried out an internal review board-approved prospective study of the delayed symptoms that occurred after 71 consecutive RFA sessions in 53 patients (12 women and 41 men; age range 45-83 years; mean age 71.6 years) with 45 primary liver tumours, 34 liver metastases, 3 renal cell carcinoma (RCC), 2 residual lesions from RCC after nephrectomy and 1 pancreatic metastases from RCC. Postablation symptoms occurred in 17 of 53 (32%) patients. Six of 17 patients developed low-grade fever (from 37.5 to 38.5 degrees C). Other symptoms included delayed pain (9/17), nausea (7/17), vomiting (3/17), malaise (3/17) and myalgia (1). Postablation syndrome is a common phenomenon after RFA of solid abdominal tumours. Not only in our study but also in the previous ones the occurrence is observed in approximately one-third patients. Patients should be informed that these symptoms are self-limiting after RFA and most patients should be able to resume near-complete preprocedural levels of activity within 10 days after the procedure.

Entities:  

Mesh:

Year:  2007        PMID: 17958690     DOI: 10.1111/j.1440-1673.2007.01871.x

Source DB:  PubMed          Journal:  Australas Radiol        ISSN: 0004-8461


  19 in total

1.  Microwave ablation therapy for treating primary and secondary lung tumours: technical note.

Authors:  G Carrafiello; M Mangini; I De Bernardi; F Fontana; G Dionigi; S Cuffari; A Imperatori; D Laganà; C Fugazzola
Journal:  Radiol Med       Date:  2010-03-29       Impact factor: 3.469

Review 2.  Percutaneous ablation in the kidney.

Authors:  Aradhana M Venkatesan; Bradford J Wood; Debra A Gervais
Journal:  Radiology       Date:  2011-11       Impact factor: 11.105

3.  Treatment of lung tumours with high-energy microwave ablation: a single-centre experience.

Authors:  Anna Maria Ierardi; Andrea Coppola; Natalie Lucchina; Gianpaolo Carrafiello
Journal:  Med Oncol       Date:  2016-11-30       Impact factor: 3.064

Review 4.  Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy.

Authors:  Serge Ginzburg; Jeffrey J Tomaszewski; Alexander Kutikov
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

5.  Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.

Authors:  Muneeb Ahmed; Luigi Solbiati; Christopher L Brace; David J Breen; Matthew R Callstrom; J William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baère; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; David Gianfelice; Alice R Gillams; Fred T Lee; Edward Leen; Riccardo Lencioni; Peter J Littrup; Tito Livraghi; David S Lu; John P McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L Pereira; Ping Liang; Hyunchul Rhim; Steven C Rose; Riad Salem; Constantinos T Sofocleous; Stephen B Solomon; Michael C Soulen; Masatoshi Tanaka; Thomas J Vogl; Bradford J Wood; S Nahum Goldberg
Journal:  J Vasc Interv Radiol       Date:  2014-10-23       Impact factor: 3.464

6.  Early Diagnosis of Intrahepatic Pseudoaneurysm during Radiofrequency Ablation using Contrast-Enhanced Ultrasound.

Authors:  S Krishna Kumar; Ong Keh Oon; Paul Horgan; Edward Leen
Journal:  Malays J Med Sci       Date:  2015-11

Review 7.  Complications of microwave and radiofrequency lung ablation: personal experience and review of the literature.

Authors:  G Carrafiello; M Mangini; F Fontana; A Di Massa; A M Ierardi; E Cotta; F Piacentino; L Nocchi Cardim; C Pellegrino; C Fugazzola
Journal:  Radiol Med       Date:  2011-10-21       Impact factor: 3.469

8.  Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial.

Authors:  M Macchi; M P Belfiore; C Floridi; N Serra; G Belfiore; L Carmignani; R F Grasso; E Mazza; C Pusceddu; L Brunese; G Carrafiello
Journal:  Med Oncol       Date:  2017-04-18       Impact factor: 3.064

9.  Percutaneous imaging-guided ablation therapies in the treatment of symptomatic bone metastases: preliminary experience.

Authors:  G Carrafiello; D Laganà; C Pellegrino; F Fontana; M Mangini; P Nicotera; M Petullà; E Bracchi; E Genovese; S Cuffari; C Fugazzola
Journal:  Radiol Med       Date:  2009-05-14       Impact factor: 3.469

Review 10.  Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies.

Authors:  Thomas J Vogl; Parviz Farshid; Nagy N N Naguib; Abbas Darvishi; Babak Bazrafshan; Emmanuel Mbalisike; Thorsten Burkhard; Stephan Zangos
Journal:  Radiol Med       Date:  2014-06-04       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.